Metrion Biosciences Cardiac Safety Screening Services
Metrion Biosciences Cardiac Safety Screening Icon Large 01 01

Specialist Cardiac Safety Screening

High-quality cardiac safety screening services, including GLP hERG and CiPA assays

Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds

Our specialist team have been developing cardiac safety assays for over twenty years.

The cardiac safety screening assays we offer include:

  • GLP hERG:
    • Generate GLP hERG data to support Investigational New Drug (IND) applications.
  • Non-GLP hERG.
  • Cardiac ion channel screening (CiPA):
    • Provide an early assessment of potential off-target effects on cardiac ion channels by studying the effect of compounds on the CiPA ion channel panel.
  • Translational cardiac assays:
    • Perform translational cardiac assays to assess potential proarrhythmic liability of compounds by determining their effect on action potentials recorded from human iPSC-derived cardiomyocytes.
    • Evaluate the effect of compounds on contractility and viability of human iPSC-derived cardiomyocytes using an impedance platform.

Cardiac safety ion channel experts

By working with us you benefit from:

  • Exceptional ion channel electrophysiology and drug discovery expertise.
  • A team of experienced cell biologists to create novel cell lines.
  • High quality, cost-effective compound screening.
  • Detailed characterisation of lead compounds in a range of high quality assays.
  • Translational services including confirmation of efficacy in stem cell and other phenotypic models.
  • Flexible approach that best suits your project and budget.
  • Rapid turn-around times, reporting and data interpretation by highly experienced ion channel scientists.

Our expertise in GLP hERG screening is demonstrated in the case study GLP hERG Assay Validation Following ICH E14/S7B 2022 Q&A Best Practice Guidelines.

GLP hERG Assay Validation  traces
Top: Example traces in vehicle, dofetilide and E-4031. Bottom: Corresponding IT plot. IC50 values generated were within 2-fold of the values reported in the ICH E14/S7B training material. Read more about GLP hERG assay validation.

Webinar recording: In Vitro Assessment of Cardiac Risk in Drug Discovery

Download the recording of this webinar to learn how an hiPSC-CM model can help provide clear decision-making data for your project team that can avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.

Recording includes presentations and Q&A:

  • Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company).
  • Steve Jenkinson (VP Drug Discovery and Safety, Metrion).
Recording web graphic

Technologies we use for cardiac safety screening

Our assay technologies include:

Cardiac Safety Screening Resource Library

Metrion Biosciences Cardiac Safety Screening Icon Large 01 01 Cardiac Safety Screening Resources
White Papers
Application notes
Cardiac Safety Screening Technologies
  • QPatch automated electrophysiology platform
  • Patchliner automated electrophysiology
  • Conventional manual patch clamp electrophysiology
  • Plate-based impedance and microelectrode array techniques
  • FlexStation plate-based imaging
Wave Background thinner 01 1

Let’s work together

What are your specific ion channel screening requirements?

If you have any questions, or would like to discuss your project, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.